SG Americas Securities LLC Acquires 42,352 Shares of Zimmer Biomet Holdings, Inc. $ZBH

SG Americas Securities LLC grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 69.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 103,462 shares of the medical equipment provider’s stock after buying an additional 42,352 shares during the period. SG Americas Securities LLC’s holdings in Zimmer Biomet were worth $9,303,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZBH. Brighton Jones LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at $204,000. Sivia Capital Partners LLC purchased a new stake in shares of Zimmer Biomet in the 2nd quarter worth about $232,000. United Bank lifted its position in shares of Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 1,153 shares during the period. J.W. Cole Advisors Inc. boosted its stake in shares of Zimmer Biomet by 14.0% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 3,906 shares of the medical equipment provider’s stock valued at $356,000 after purchasing an additional 481 shares in the last quarter. Finally, Choreo LLC increased its position in shares of Zimmer Biomet by 3.7% during the second quarter. Choreo LLC now owns 12,913 shares of the medical equipment provider’s stock valued at $1,181,000 after buying an additional 466 shares during the period. Institutional investors own 88.89% of the company’s stock.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.70% of the stock is currently owned by company insiders.

Zimmer Biomet Trading Down 0.2%

Shares of NYSE ZBH opened at $88.41 on Monday. Zimmer Biomet Holdings, Inc. has a 1 year low of $84.59 and a 1 year high of $114.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The firm has a 50-day moving average of $92.00 and a 200 day moving average of $94.01. The stock has a market cap of $17.30 billion, a P/E ratio of 24.98, a price-to-earnings-growth ratio of 1.81 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. During the same quarter in the prior year, the company earned $2.31 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ZBH shares. Robert W. Baird reissued a “neutral” rating and issued a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. Wells Fargo & Company lifted their price objective on Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Weiss Ratings downgraded Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, March 23rd. TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Finally, UBS Group restated a “sell” rating and set a $89.00 price target on shares of Zimmer Biomet in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $106.20.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.